De grootste kennisbank van het HBO

Inspiratie op jouw vakgebied

Vrij toegankelijk

Terug naar zoekresultatenDeel deze publicatie

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Rechten:

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Rechten:

Samenvatting

Accurate assessment of TP53 gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li–Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of information on cancer gene alterations and have confirmed TP53 as the most commonly mutated gene in human cancer. Analysis of a database of 70,000 TP53 variants reveals that the two newly discovered exons of the gene, exons 9b and 9g, generated by alternative splicing, are the targets of inactivating mutation events in breast, liver, and head and neck tumors. Furthermore, germline rearrangements in intron 1 of TP53 are associated with LFS and are frequently observed in sporadic osteosarcoma. In this context of constantly growing genomic data, we discuss how screening strategies must be improved when assessing TP53 status in clinical samples. Finally, we discuss how TP53 alterations should be described by using accurate nomenclature to avoid confusion in scientific and clinical reports.

Toon meer
OrganisatieHogeschool Leiden
AfdelingFaculteit Techniek
LectoraatGenome-based Health
Gepubliceerd inCancer Research Vol. 77, Uitgave: 6, Pagina's: 1250-1260
Datum2017-03-14
TypeArtikel
DOI 10.1158/0008-5472.CAN-16-2179
TaalEngels

Op de HBO Kennisbank vind je publicaties van 26 hogescholen

De grootste kennisbank van het HBO

Inspiratie op jouw vakgebied

Vrij toegankelijk